{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T09:00:59Z","timestamp":1770541259994,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1038\/s41433-022-02338-2","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T12:04:23Z","timestamp":1670933063000},"page":"2310-2315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3984-6014","authenticated-orcid":false,"given":"Emilie","family":"Dobler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bashar Raouf","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randhir","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peck Lin","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arijit","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"2338_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4239\/wjd.v2.i6.98","volume":"2","author":"P Romero-Aroca","year":"2011","unstructured":"Romero-Aroca P. Managing diabetic macular edema: The leading cause of diabetes blindness. World J Diabetes. 2011;2:98.","journal-title":"World J Diabetes"},{"key":"2338_CR2","doi-asserted-by":"crossref","unstructured":"Photocoagulation for Diabetic Macular Edema. Early treatment diabetic retinopathy study report number 1 Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1985;103:1796\u2013806.","DOI":"10.1001\/archopht.1985.01050120030015"},{"key":"2338_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/dme.12089","volume":"30","author":"L Heng","year":"2013","unstructured":"Heng L, Comyn O, Peto T, Tadros C, Ng E, Sivaprasad S, et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet Med. 2013;30:640\u201350.","journal-title":"Diabet Med"},{"key":"2338_CR4","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Wells JA, Glassman AR, Ayala AR. Diabetic Retinopathy Clinical Research Network, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N. Engl J Med. 2015;372:1193\u2013203.","journal-title":"N. Engl J Med"},{"key":"2338_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"V Gonzalez","year":"2016","unstructured":"Gonzalez V, Campbell J, Holekamp N, Kiss S, Loewenstein A, Augustin A, et al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol. 2016;172:72\u201379.","journal-title":"Am J Ophthalmol"},{"key":"2338_CR6","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"D Boyer","year":"2014","unstructured":"Boyer D, Yoon Y, Belfort R, Bandello F, Maturi R, Augustin A, et al. Three-year, randomized, sham-controlled trial of Dexamethasone Intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904\u201314.","journal-title":"Ophthalmology"},{"key":"2338_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/eye.2015.110","volume":"29","author":"W Amoaku","year":"2015","unstructured":"Amoaku W, Saker S, Stewart E. A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye 2015;29:1115\u201330.","journal-title":"Eye"},{"key":"2338_CR8","unstructured":"Ozurdex Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/23422 (Accessed 5 May 2022)"},{"key":"2338_CR9","unstructured":"ILUVIEN Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/27636 (Accessed 5 May 2022)"},{"key":"2338_CR10","unstructured":"National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (NICE Guideline Number TA301). 2013. https:\/\/www.nice.org.uk\/guidance\/ta301"},{"key":"2338_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","volume":"120","author":"P Campochiaro","year":"2013","unstructured":"Campochiaro P, Nguyen Q, Hafiz G, Bloom S, Brown D, Busquets M, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology 2013;120:583\u20137.","journal-title":"Ophthalmology"},{"key":"2338_CR12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","volume":"118","author":"P Campochiaro","year":"2011","unstructured":"Campochiaro P, Brown D, Pearson A, Ciulla T, Boyer D, Holz F, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626\u201335. e2","journal-title":"Ophthalmology"},{"key":"2338_CR13","doi-asserted-by":"publisher","unstructured":"Singer M, Sheth V, Mansour S, Coughlin B, Gonzalez V, Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic Macular Edema. Ophthalmology (2022). https:\/\/doi.org\/10.1016\/j.ophtha.2022.01.015","DOI":"10.1016\/j.ophtha.2022.01.015"},{"key":"2338_CR14","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/bjophthalmol-2018-312284","volume":"103","author":"U Chakravarthy","year":"2019","unstructured":"Chakravarthy U, Taylor SR, Koch FH, Castro de Sousa JP, Bailey C. ILUVIEN Registry Safety Study (IRISS) Investigators Group. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2019;103:1072\u20137.","journal-title":"Br J Ophthalmol"},{"key":"2338_CR15","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41433-021-01542-w","volume":"36","author":"C Bailey","year":"2021","unstructured":"Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J. Extended real-world experience with the ILUVIEN\u00ae (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft\u00ae audit study. Eye 2021;36:1012\u20138.","journal-title":"Eye"},{"key":"2338_CR16","first-page":"2935","volume":"15","author":"B Mushtaq","year":"2021","unstructured":"Mushtaq B, Bhatnagar A, Palmer H. Real-world outcomes in diabetic macular Edema for the 0.2 \u03bcg\/Day fluocinolone acetonide implant: case series from the Midlands, UK. Clinical. Ophthalmology. 2021;15:2935\u201343. Volume","journal-title":"Ophthalmology"},{"key":"2338_CR17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/eye.2016.301","volume":"31","author":"F Alfaqawi","year":"2017","unstructured":"Alfaqawi F, Lip P, Elsherbiny S, Chavan R, Mitra A, Mushtaq B. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Eye 2017;31:650\u20136.","journal-title":"Eye"},{"key":"2338_CR18","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"N Gregori","year":"2010","unstructured":"Gregori N, Feuer W, Rosenfeld P. Novel method for analyzing snellen visual acuity measurements. Retina 2010;30:1046\u201350.","journal-title":"Retina"},{"key":"2338_CR19","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"P Campochiaro","year":"2012","unstructured":"Campochiaro P, Brown D, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic Macular Edema. Ophthalmology. 2012;119:2125\u201332.","journal-title":"Ophthalmology"},{"key":"2338_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ajo.2020.03.016","volume":"215","author":"M Cicinelli","year":"2020","unstructured":"Cicinelli M, Rabiolo A, Zollet P, Capone L, Lattanzio R, Bandello F. Persistent or recurrent diabetic Macular Edema after Fluocinolone Acetonide 0.19 mg implant: risk factors and management. Am J Ophthalmol. 2020;215:14\u201324.","journal-title":"Am J Ophthalmol"},{"key":"2338_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ophtha.2006.06.052","volume":"114","author":"DJ Browning","year":"2007","unstructured":"Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Fong DS, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525\u201336.","journal-title":"Ophthalmology"},{"key":"2338_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jamaophthalmol.2018.3848","volume":"136","author":"G De\u00e1k","year":"2018","unstructured":"De\u00e1k G, Schmidt-Erfurth U, Jampol L. Correlation of central retinal thickness and visual acuity in diabetic Macular Edema. JAMA Ophthalmol. 2018;136:1215.","journal-title":"JAMA Ophthalmol"},{"key":"2338_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/bjophthalmol-2017-310483","volume":"102","author":"B Gerendas","year":"2017","unstructured":"Gerendas B, Prager S, Deak G, Simader C, Lammer J, Waldstein S, et al. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema. Br J Ophthalmol. 2017;102:195\u2013203.","journal-title":"Br J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02338-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02338-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02338-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:24:25Z","timestamp":1744158265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02338-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2338"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-02338-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E Dobler\u2014none. BR Mohammed\u2014received educational travel sponsorship from Bayer and Novartis and attended educational meeting sponsored by Alimera. R Chavan\u2013received speaker fees and travel grants from Novartis, Bayer, and Allergan. PL Lip\u2014none. A Mitra\u2014consultant for Roche, Novartis, Alimera Sciences, and Allergan. B Mushtaq - advisory board member and consultant for Novartis, Bayer, Allergan, and Alimera sciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}